Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex

Journal of Immunology

Volumn 176, Issue 4, 2006, Pages 2330-2336

  Pittet, Mikaël J ^a,f   Gati, Asma ^b   Le Gal, Frederic Anne ^c   Bioley, Gilles ^a   Guillaume, Philippe ^d   De Smedt, Magda ^e   Plum, Jean ^e   Speiser, Daniel E ^a   Cerottini, Jean Charles ^d   Dietrich, Pierre Yves ^c   Romero, Pedro ^a,b   Zippelius, Alfred ^b,g  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ALLOIMMUNITY; AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FLOW CYTOMETRY; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LYMPHOCYTE CLONE; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; THYMOCYTE; TUMOR CELL;

EID: 32044467732     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.4.2330     Document Type: Article

References (41)

1. Lechler, R. I., G. Lombardi, J. R. Batchelor, N. Reinsmoen, and F. H. Bach. 1990. The molecular basis of alloreactivity. Immunol. Today 11: 83-88.
2. Sherman, L. A., and S. Chattopadhyay. 1993. The molecular basis of allorecognition. Annu. Rev. Immunol. 11: 385-402.
3. Bevan, M. J. 1984. High determinant density may explain the phenomenon of alloreactivity. Immunol. Today 5: 128-130.
4. Smith, P. A., A. Brunmark, M. R. Jackson, and T. A. Potter. 1997. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J. Exp. Med. 185: 1023-1033.
5. Rotzschke, O., K. Falk, S. Faath, and H. G. Rammensee. 1991. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 174: 1059-1071.
6. Rammensee, H. G., and M. J. Bevan. 1984. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 308: 741-744.
7. Matzinger, P., and M. J. Bevan. 1977. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell. Immunol. 29: 1-5.
8. Obst, R., C. Munz, S. Stevanovic, and H. G. Rammensee. 1998. Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire. Eur. J. Immunol. 28: 2432-2443.
9. Munz, C., R. Obst, W. Osen, S. Stevanovic, and H. G. Rammensee. 1999. Alloreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 162: 25-34.
10. Sykulev, Y., A. Brunmark, T. J. Tsomides, S. Kageyama, M. Jackson, P. A. Peterson, and H. N. Eisen. 1994. High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. Proc. Natl. Acad. Sci. USA 91: 11487-11491.
11. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, H. J. Stauss, and M. Theobald. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2: 962-970.
12. Sadovnikova, E., L. A. Jopling, K. S. Soo, and H. J. Stauss. 1998. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class 1 molecules. Eur. J. Immunol. 28: 193-200.
13. Jiang, Y. Z., E. J. Kanfer, D. Macdonald, J. O. Cullis, J. M. Goldman, and A. J. Barrett. 1991. Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant. 8: 253-258.
14. Giralt, S. A., and H. J. Kolb. 1996. Donor lymphocyte infusions. Curr. Opin. Oncol. 8: 96-102.
15. Sadovnikova, E., and H. J. Stauss. 1996. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 93: 13114-13118.
16. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. [Published erratum appears in 1998 Science 280:1821.] Science 274: 94-96.
17. Moris, A., V. Teichgraber, L. Gauthier, H. J. Buhring, and H. G. Rammensee. 2001. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J. Immunol. 166: 4818-4821.
18. - donor: exploring tumor antigen allorestricted recognition. Cancer Immun. 2: 7-11.
19. Dietrich, P. Y., F. A. Le Gal, V. Dutoit, M. J. Pittet, L. Trautman, A. Zippelius, I. Cognet, V. Widmer, P. R. Walker, O. Michielin, et al. 2003. Prevalent role of TCR α-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J. Immunol. 170: 5103-5109.
20. Mantovani, S., B. Palermo, S. Garbelli, R. Campanelli, G. Robustelli Della Cuna, R. Gennari, F. Benvenuto, E. Lantelme, and C. Giachino. 2002. Dominant TCR-α requirements for a self antigen recognition in humans. J. Immunol. 169: 6253-6260.
21. Zippelius, A., M. J. Pittet, P. Batard, N. Rufer, M. de Smedt, P. Guillaume, K. Ellefsen, D. Valmori, D. Liénard, J. Plum, et al. 2002. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195: 485-494.
22. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class 1 major histocompatibility complex tetramers reveals high numbers of antigen- experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188: 1641-1650.
23. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160: 1750-1758.
24. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune. D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64: 2865-2873.
25. Genevee, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22: 1261-1269.
26. Arden, B., S. P. Clark, D. Kabelitz, and T. W. Mak. 1995. Human T-cell receptor variable gene segment families. Immunogenetics 42: 455-500.
27. Pittet, M. J., V. Rubio-Godoy, G. Bioley, P. Guillaume, P. Batard, D. Speiser, I. Luescher, J. C. Cerottini, P. Romero, and A. Zippelius. 2003. alpha3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J. Immunol. 171: 1844-1849.
28. + T cells in humans. J. Exp. Med. 196: 207-216.
29. Dietrich, P. Y., P. R. Walker, A. L. Quiquerez, G. Perrin, V. Dutoit, D. Liénard, P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2001. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res. 61: 2047-2054.
30. Valmori, D., V. Dutoit, V. Schnuriger, A. L. Quiquerez, M. J. Pittet, P. Guillaume, V. Rubio-Godoy, P. R. Walker, D. Rimoldi, D. Lienard, et al. 2002. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J. Immunol. 168: 4231-4240.
31. Argaet, V. P., C. W. Schmidt, S. R. Burrows, S. L. Silins, M. G. Kurilla, D. L. Doolan, A. Suhrbier, D. J. Moss, E. Kieff, and T. B. Suclley. 1994. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180: 2335-2340.
32. McHeyzer-Williams, M. G., and M. M. Davis. 1995. Antigen-specific development of primary and memory T cells in vivo. Science 268: 106-111.
33. Romero, P., D. Valmori, M. J. Pittet, A. Zippelius, D. Rimoldi, F. Levy, V. Dutoit, M. Ayyoub, V. Rubio-Godoy, O. Michielin, et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188: 81-96.
34. Moris, A., D. Wernet, S. Stevanovic, and H. G. Rammensee. 2001. The peptide-specific alloreactive human T cell repertoire varies largely between individuals and is not extended in HLA-A*0205-anti-HLA-A*0201 pairings. Int. Immunol. 13: 863-870.
35. Savage, P., L. Gao, K. Vento, P. Cowburn, S. Man, N. Steven, G. Ogg, A. McMichael, A. Epenetos, E. Goulmy, and H. J. Stauss. 2004. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103: 4613-4615.
36. Obst, R., N. Netuschil, K. Klopfer, S. Stevanovic, and H. G. Rammensee. 2000. The role of peptides in T cell alloreactivity is determined by self-major histocompatibility complex molecules. J. Exp. Med. 191: 805-812.
37. Guimezanes, A., T. N. Schumacher, H. L. Ploegh, and A. M. Schmitt-Verhulst. 1992. A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class 1 product. Eur. J. Immunol. 22: 1651-1654.
38. Heath, W. R., K. P. Kane, M. F. Mescher, and L. A. Shennan. 1991. Alloreactive T cells discriminate among a diverse set of endogenous peptides. Proc. Natl. Acad. Sci. USA 88: 5101-5105.
39. Heath, W. R., and L. A. Sherman. 1991. Cell-type-specific recognition of allogeneic cells by alloreactive cytotoxic T cells: a consequence of peptide-dependent allorecognition. Eur. J. Immunol. 21: 153-159.
40. + cytotoxic T lymphocytes in association with a class 1 MHC protein. Cell 69: 989-998.
41. Moss, P. A., W. M. Rosenberg, and J. I. Bell. 1992. The human T cell receptor in health and disease. Annu. Rev. Immunol. 10: 71-96.